[go: up one dir, main page]

US20180028662A1 - Method for Suppressing Bitterness of Quinoline Derivative - Google Patents

Method for Suppressing Bitterness of Quinoline Derivative Download PDF

Info

Publication number
US20180028662A1
US20180028662A1 US15/550,124 US201615550124A US2018028662A1 US 20180028662 A1 US20180028662 A1 US 20180028662A1 US 201615550124 A US201615550124 A US 201615550124A US 2018028662 A1 US2018028662 A1 US 2018028662A1
Authority
US
United States
Prior art keywords
pharmaceutically acceptable
acceptable salt
basic substance
bitterness
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/550,124
Other languages
English (en)
Inventor
Kentaro Nagane
Yosuke Ueki
Shusuke Sano
Takahisa Sakaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56789022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20180028662(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to US15/550,124 priority Critical patent/US20180028662A1/en
Assigned to EISAI R&D MANAGEMENT CO., LTD. reassignment EISAI R&D MANAGEMENT CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UEKI, YOSUKE, SAKAGUCHI, TAKAHISA, SANO, SHUSUKE, NAGANE, KENTARO
Publication of US20180028662A1 publication Critical patent/US20180028662A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a method for suppressing bitterness of a medicine.
  • Patent Literature 1 4-(3-Chloro-4-(cydopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide (hereinafter also referred to as Compound 1 or lenvatinib) or a salt thereof, which is a quinoline derivative having an antiangiogenic effect, is known (Patent Literature 1).
  • a pharmaceutical composition comprising Compound 1 or a salt thereof
  • a pharmaceutical composition comprising Compound 1 or a salt thereof and (i) a compound, a 5% (w/w) solution or suspension of which has a pH of 8 or more and/or (ii) a silicic acid to reduce a degradation under humidified and heated conditions or inhibit a gelation on a surface of the pharmaceutical composition (Patent Literature 2).
  • Patent Literature 3 As a pharmaceutical composition excellent in dissolution properties of Compound 1 and stable through long-term storage, a pharmaceutical composition comprising (1) Compound 1 or a salt thereof; and (2) a basic substance is known (Patent Literature 3).
  • composition comprising a pharmacologically active ingredient of an organic sulfonate, a disintegrating agent and a water-soluble salt, a 2.5% aqueous solution of which has a pH of 3 to 9 (Patent Literature 4).
  • Patent Literature 1 U.S. Patent Application Publication No. 2004/0053908
  • Patent Literature 2 U.S. Patent Application Publication No. 2008/0214604
  • Patent Literature 4 U.S. Patent Application Publication No. 2008/0214557
  • a pharmaceutical composition such as a capsule dissolved or suspended in water or the like is administered in some cases from the viewpoint of medication compliance. If a drug having bitterness dissolved or suspended in water or the like is administered to a patient, however, it is apprehended that the patient may have trouble taking the drug due to the bitterness, and this tendency is increased if the patient is a child.
  • an administration form that can be easily swallowed, such as a suspension is sometimes employed, but due to the size of the digestive tract of the child, there is an upper limit in the amount of a solvent used for the suspension.
  • due to the physical properties of an active pharmaceutical ingredient such as consistency and solubility, not only the bitterness but also the active pharmaceutical ingredient contained in the suspension may remain in a vessel, and thus, the recovery may not be sufficient in some cases.
  • Compound 1 or a pharmaceutically acceptable salt thereof has bitterness.
  • the present inventors have found that the bitterness of Compound 1 or the pharmaceutically acceptable salt thereof can be suppressed by mixing a basic substance such as calcium carbonate with Compound 1 or the pharmaceutically acceptable salt thereof.
  • an administration method comprising: 1) suspending, in an aqueous solvent in a vessel, a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof and a basic substance; 2) administering a suspension obtained in 1) from the vessel to a patient 3) rinsing the vessel with an aqueous solvent; and 4) administering a rinsing solution obtained in 3) to the patient is employed, the suspension of Compound 1 can be administered to a child at high recovery without causing the child to feel bitterness and in a liquid amount administrable to the child.
  • the present invention provides the following [1] to [33]:
  • [1] A method for suppressing bitterness of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide, comprising mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or a pharmaceutically acceptable salt thereof and a basic substance.
  • [2] The method according to [1], wherein 0.01 to 50 parts by weight of the basic substance is mixed per 1 part by weight of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or the pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or a pharmaceutically acceptable salt thereof, and a basic substance in an amount effective for suppressing bitterness.
  • a pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or a pharmaceutically acceptable salt thereof, the pharmaceutical composition comprising means for mixing a basic substance for suppressing bitterness.
  • a pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or a pharmaceutically acceptable salt thereof and a basic substance, the pharmaceutical composition having bitterness suppressed.
  • the pharmaceutical composition according to any one of [8] to [10], comprising 0.01 to 50 parts by weight of the basic substance per 1 part by weight of 4-(3-chloro-4-(cydopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or the pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition according to any one of [8] to [16] in a dosage form of an orally disintegrating tablet, a chewable preparation, an effervescent tablet, a dispersible tablet, a soluble tablet, a syrup, a preparation for a syrup, a troche, or an oral liquid preparation.
  • the pharmaceutical composition according to any one of [8] to [16] being a preparation that can be suspended in an aqueous solvent upon an administration to prepare a suspension.
  • a bitterness suppressing agent comprising a basic substance, for 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or a pharmaceutically acceptable salt thereof.
  • the bitterness suppressing agent according to [19], wherein the basic substance added is in an amount of 0.01 to 50 parts by weight per 1 part by weight of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or the pharmaceutically acceptable salt thereof.
  • the bitterness suppressing agent according to [19], wherein the basic substance added is in an amount of 0.16 to 80 mol per 1 mol of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or the pharmaceutically acceptable salt thereof.
  • bitterness suppressing agent according to any one of [19] to [21], wherein the basic substance is calcium carbonate.
  • a method for administering a suspension comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or a pharmaceutically acceptable salt thereof, and a basic substance
  • the method comprising: 1) suspending, in an aqueous solvent in a vessel, a pharmaceutical composition comprising 1 to mg of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or the pharmaceutically acceptable salt thereof, and the basic substance; 2) administering a suspension obtained in 1) to a patient from the vessel; 3) rinsing the vessel with an aqueous solvent; and 4) administering a rinsing solution obtained in 3) to the patient.
  • a method for treating a cancer by administering a suspension containing 1 to 24 mg of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxyamide or a pharmaceutically acceptable salt thereof, and a basic substance.
  • Compound 1 or a pharmaceutically acceptable salt thereof is known as an anticancer agent for thyroid cancer and the like, and a cancer can be treated without causing a patient to feel bitterness upon drug administration by the method of the present invention.
  • FIG. 1 is a diagram illustrating relative comparison of bitterness of lenvatinib mesylate and quinine hydrochloride.
  • FIG. 2 is a diagram illustrating concentration dependence of the bitterness suppressing effect of calcium carbonate.
  • FIG. 3 is a diagram illustrating concentration dependence of the bitterness suppressing effect of magnesium oxide.
  • FIG. 4 is a diagram illustrating the bitterness suppressing effect of various polymers.
  • FIG. 5 is a diagram illustrating the bitterness suppressing effect of various low molecular weight compounds.
  • FIG. 6 is a diagram illustrating the bitterness suppressing effect of a lenvatinib mesylate-containing composition.
  • FIG. 7 is a diagram illustrating the bitterness suppressing effect of respective components of the lenvatinib mesylate-containing composition.
  • FIG. 8 is a diagram illustrating results of a dissolution test of orally disintegrating tablets.
  • FIG. 9 is a diagram illustrating the bitterness suppressing effect of a lenvatinib mesylate-containing composition.
  • FIG. 10 is a diagram illustrating the bitterness suppressing effect of various low molecular weight compounds.
  • FIG. 11 is a diagram illustrating the bitterness suppressing effect of various low molecular weight compounds.
  • FIG. 12 is a diagram illustrating the bitterness suppressing effect of various silicic acid compounds.
  • a basic substance may be a low molecular weight compound or a high molecular weight compound as long as it is a substance exhibiting basicity
  • preferable examples include a basic oxide, a basic carbonate, a basic hydroxide or a sodium salt of a polymer having a carboxyl group, and it is more preferably calcium carbonate, magnesium carbonate, potassium carbonate, magnesium oxide, magnesium hydroxide, sodium carboxymethyl starch or croscarmellose sodium, further preferably calcium carbonate or magnesium oxide, and most preferably calcium carbonate.
  • the basic substance is a low molecular weight compound, preferably 0.16 to 80 mol, more preferably 0.3 to 60 mol, and most preferably 0.5 to 40 mol of the basic substance is mixed per 1 mol of Compound 1.
  • a pharmaceutically acceptable salt means a hydrochloride, a hydrobromide, a tosylate, a sulfate, a mesylate or an esylate, and is preferably a mesylate.
  • the “bitterness” of Compound 1 or the pharmaceutically acceptable salt thereof is measured by the following method.
  • a solution of Compound 1 at a concentration of 8 mg/mL as a free form is prepared by dissolving Compound 1 or the pharmaceutically acceptable salt thereof in a 10 mM potassium chloride aqueous solution.
  • an additive is added if necessary, and the resultant is stirred for 30 minutes and then centrifuged to give a liquid phase component.
  • the bitterness of the liquid phase component is measured using a taste sensor (AC0) for measuring bitterness, and the thus obtained value is used as a bitterness index.
  • AC0 taste sensor
  • the term “suppress the bitterness” of Compound 1 or the pharmaceutically acceptable salt thereof means that as measured “bitterness” according to the above-described method, the relative ratio of a measured value of a sample obtained by adding an additive into a control, which comprising Compound 1 or the pharmaceutically acceptable salt thereof, to a measured value of the control is less than 100%, and preferably 70% or less.
  • the control comprising Compound 1 or the pharmaceutically acceptable salt thereof may be Compound 1 itself or the pharmaceutically acceptable salt thereof itself, or may be a mixture also comprising an additional component (such as a capsule) if necessary.
  • a pharmaceutical composition of the present invention is not particularly limited as long as it is a preparation in which the bitterness of Compound 1 or the pharmaceutically acceptable salt thereof may possibly be felt in a usual administration method or in an administration method comprising dissolving or suspending in water or the like without impairing a specific function such as an enteric property.
  • Examples of a preferable form include an orally disintegrating tablet, a chewable preparation, an effervescent tablet, a dispersible tablet, a soluble tablet, a syrup, a preparation for a syrup, a troche and an oral liquid preparation, which stay hi oral cavity for a comparatively long period of time and hence possibly cause a patient to feel the bitterness.
  • a dosage form of a capsule or the like can be included in the preferable form if an oral liquid preparation can be prepared from the preparation at time of use using a solvent such as water.
  • the pharmaceutical composition of the present invention can be produced by any of known methods such as methods described in The Japanese Pharmacopoeia, Sixteenth Edition, General Rules for Preparations.
  • a granule can be produced by adding, if necessary, a diluting agent, a binding agent, a disintegrator, a solvent or the like to Compound 1 or the pharmaceutically acceptable salt thereof; and subjecting the resultant to stirring granulation, extrusion granulation, oscillating granulation, fluidized bed granulation, spray granulation or the like.
  • a core substance of a purified sucrose spherical granule, a lactose-crystalline cellulose spherical granule, a sucrose-starch spherical granule or a granular crystalline cellulose may be coated with an epipastic comprising an additive such as water, sucrose, hydroxypropylcellulose, methylcellulose or polyvinylpyrrolidone.
  • the resultant may be further sized or ground.
  • a suspension prepared by suspending a mixture (including a dosage form such as a tablet or a capsule) of 1 to 24 mg of Compound 1 or the pharmaceutically acceptable salt thereof with a basic substance in an aqueous solvent in a vessel such as a vial, a syringe or a syringe equipped with a nasogastric tube (NG tube).
  • the amount of the aqueous solvent used for the suspension (which can be a sweet drink such as an apple juice according to patients preference) is preferably 1 to 10 mL, more preferably 2 to 5 mL and further preferably about 3 mL.
  • the mixture At the time of suspending, it is preferable to allow the mixture to stand still for a while, preferably about 10 minutes, after adding the aqueous solvent, and then to shake the resultant for a while, preferably about 3 minutes.
  • the vessel used for the suspension may be rinsed with 1 to 10 mL, more preferably 1 to 5 mL and further preferably about 2 mL of an aqueous solvent, and the resultant rinsing solution may be further administered.
  • a numerical value with the term “about” encompasses a numerical value obtained by rounding off to the nearest whole number, and for example, “about 3” corresponds to a range of 2.5 to 3.4.
  • Crystalline Asahi Kasei Ceolus PH-101 Cellulose Chemicals Japanese (PH101) Corporation Pharmacopoeia Hydroxypropyl- Nippon Soda HPC-L cellulose Co., Ltd. Low-substituted Shin-Etsu L-HPC LH-21 Hydroxypropyl- Chemical cellulose Co., Ltd. Crystalline Asahi Kasei Ceolus PH-102, Cellulose Chemicals Japanese (PH102) Corporation Pharmacopoeia Talc Matsumura Hi-Filler #17 Sangyo Co., Ltd.
  • Relative bitterness to Reference Example 7(%) (Measured value of each sample ⁇ Measured value of 10 mM potassium chloride aqueous solution)/(Measured value of Reference Example 7 ⁇ Measured value of 10 mM potassium chloride aqueous solution) ⁇ 100%
  • Lenvatinib mesylate was dissolved in a 10 mM potassium chloride aqueous solution to a concentration of 9.8 mg/mL.
  • the measurement with the taste perception apparatus was performed four times on each sample, and three measurement results of the second to fourth measurements were used for the analysis.
  • the relative bitterness to Comparative Example 1 was calculated in accordance with the following equation, and an average of the three measured values is shown in Table 5 and FIG. 2 . It is noted that the relative bitterness was calculated using merely data obtained through a series of continuous measurements.
  • Relative bitterness to Comparative Example 1 (Measured value of each sample ⁇ Measured value of 10 mM potassium chloride aqueous solution)/(Measured value of Comparative Example 1 ⁇ Measured value of 10 mM potassium chloride aqueous solution) ⁇ 100%
  • Example 1 Lenvatinib Mesylate 9.8 9.8 9.8 9.8 9.8 9.8 9.8 (mg/mL) Calcium Carbonate 26.4 2.64 1.32 0.66 0.26 0.026 (mg/mL) Molar Ratio 14.1 1.41 0.70 0.35 0.14 0.01 (Additive/Lenvatinib Mesylate) Relative Bitterness to 46% 44% 43% 66% 80% 92% 100% Comparative Example 1 (%)
  • lenvatinib mesylate 9.8 mg/mL of lenvatinib mesylate is equivalent to 8 mg/mL of a free form of lenvatinib.
  • Example 1 Lenvatinib Mesylate 9.8 9.8 9.8 9.8 9.8 9.8 9.8 9.8 9.8 9.8 (mg/mL) Magnesium Oxide 26.4 2.64 1.32 0.66 0.26 0.026 (mg/mL) Molar Ratio 35.0 3.50 1.75 0.87 0.35 0.03 (Additive/Lenvatinib Mesylate) Relative Bitterness to 16% 12% 9% 7% 44% 89% 100% Comparative Example 1 (%)
  • lenvatinib mesylate 9.8 mg/mL of lenvatinib mesylate is equivalent to 8 mg/mL of a free form of lenvatinib.
  • lenvatinib mesylate 9.8 mg/mL of lenvatinib mesylate is equivalent to 8 mg/mL of a free form of lenvatinib.
  • the measurement sample of Example 18 was prepared by the following method: The amounts of respective raw materials used in preparation of a sized granule are shown in Table 10. Lenvatinib mesylate and calcium carbonate were charged and mixed in a vertical granulator. To thus obtained mixture, mannitol, crystalline cellulose (PH101) and low-substituted hydroxypropylcellulose were added to be mixed in the vertical granulator. To the resultant mixture, an aqueous solution of hydroxypropylcellulose and an appropriate amount of purified water were gradually added in this order under stirring. After completing the addition, the resultant was further stirred in the vertical granulator to obtain a granulated granule.
  • the granulated granule was dried using a fluidized bed with an inlet air temperature set to 70° C., and the resultant was sized using a Comil equipped with a screen having a pore size of 1 mm to obtain a sized granule.
  • the sized granule, crystalline cellulose (PH102) and talc were mixed in a tumbler mixer to obtain a composition comprising lenvatinib mesylate, the composition of which is shown in Table 9.
  • the resultant was stirred for 30 minutes with a stirrer. After stirring, the centrifugation operation described in (3) of Test Example 2 was performed to collect a supernatant portion as a measurement sample.
  • Example 18 As a result, it was found that the relative bitterness of Example 18 to Comparative Example 1 was 70% or less.
  • compositions of measurement samples and measurement results of the relative bitterness of Example 19 and Comparative Examples 1 and 11 to 15 to Comparative Example 1 are shown in Table 11 and FIG. 7 .
  • the measurement of the relative bitterness was performed in the same manner as in Test Example 2. In this examination, the bitterness suppressing effect of each component of the lenvatinib mesylate-containing composition of Example 18 was evaluated.
  • the measurement sample of Example 25 was prepared by the following method.
  • a 10 mM potassium chloride aqueous solution was added to a concentration shown in Table 16, and the resultant was stirred for 30 minutes with a stirrer. After stirring, the centrifugation operation described in (3) of Test Example 2 was performed to collect a supernatant portion as a measurement sample.
  • Example 1 Lenvatinib Mesylate (mg/mL) 9.8 a) 9.8 Calcium Carbonate (mg/mL) 26.4 a) Mannitol(mg/mL) 7.0 a) Crystalline Cellulose (PH101) (mg/mL) 8.0 a) Hydroxypropylcellulose (mg/mL) 2.4 a) Low-substituted Hydroxypropylcellulose 20.0 a) (mg/mL) Crystalline Cellulose (PH102) (mg/mL) 4.0 Talc(mg/mL) 2.4 No. 4 Hypromellose Capsule (Capsule/mL) 0.8 Relative Bitterness to Comparative 22% 100% Example 1 (%)
  • lenvatinib mesylate 9.8 mg/mL of lenvatinib mesylate is equivalent to 8 mg/mL of a free form of lenvatinib.
  • lenvatinib mesylate 9.8 mg/mL of lenvatinib mesylate is equivalent to 8 mg/mL of a free form of lenvatinib.
  • lenvatinib mesylate 9.8 mg/mL of lenvatinib mesylate is equivalent to 8 mg/mL of a free form of lenvatinib.
  • Capsules described in Examples 1 to 3 of U.S. Patent Application Publication No. 2012/0077842 were put in the 20 mL vial (specifically, one to five capsules were put in the vial).
  • the vial was closed with the screw cap, and was allowed to stand still for about 10 minutes.
  • the vial was shaken for about 3 minutes to dissolve capsule shell and suspend a granule, and the cap of the vial was removed to administer 3 mL of the thus obtained suspension contained in the vial to a patient.
  • the vial was shaken ten times, and the cap of the vial was removed to administer 2 mL of the resultant rinsing solution contained in the vial to the patient.
  • the total amount of the suspension and the rinsing solution to be administered per one to five capsules was 5 mL.
  • a piston was pushed into the end of the syringe by about 2 cm, and the syringe was allowed to stand still for about 10 minutes. After standing for 10 minutes, the syringe was shaken for about 3 minutes to dissolve capsule shell and suspend a granule. The cap was removed from the syringe, the piston was slid to remove the air from the syringe, and 3 mL of the thus obtained suspension was administered from the syringe to a patient.
  • the piston was pushed into the end of the syringe by about 2 cm, followed by shaking ten times.
  • the cap was removed from the syringe, the piston was slid to remove the air from the syringe, and 2 mL of the resultant rinsing solution was administered to the patient.
  • the total amount of the suspension and the rinsing solution to be administered per one to five capsules was 5 mL.
  • a piston was pushed into the end of the syringe by about 2 cm, and the syringe was allowed to stand still for about 10 minutes. After standing for 10 minutes, the syringe was shaken for about 3 minutes to dissolve capsule shell and suspend a granule. The cap was removed from the syringe, and the piston was slid to remove the air from the syringe.
  • the NG tube was attached to the syringe, and 3 mL of the thus obtained suspension was administered through the NG tube to a patient.
  • the NG tube was removed from the syringe, and the cap was attached to the syringe again.
  • the piston was pushed into the end of the syringe by about 2 cm, and then, the syringe was shaken ten times.
  • the cap was removed from the syringe, and the piston was slid to remove the air from the syringe.
  • the NG tube was attached to the syringe, and 2 mL of the resultant rinsing solution was administered through the NG tube to the patient.
  • the total amount of the suspension and the rinsing solution to be administered per one to five capsules was 5 mL.
  • Screw cap and vial (20 mL, manufactured by Niommenrika-Glass Co., Ltd.)
  • Apple juice (100%, manufactured by Dole Food Company, Inc.)
  • a vial was charged with one 1, 4 or 10 mg lenvatinib capsule or five capsules of a total lenvatinib amount of 17 mg (namely, three 1 mg capsules, one 4 mg capsule and one 10 mg capsule).
  • 3 mL of water or the apple juice was added thereto using a syringe, and the vial was closed with the cap.
  • the resultant vial was allowed to stand still for about 10 minutes, and then was shaken for about 3 minutes to dissolve capsule shell.
  • the thus obtained suspension was taken out of the vial, and was subjected to dilution and centrifugation to prepare a sample liquid.
  • a 20 mL syringe was charged with one 1, 4 or 10 mg lenvatinib capsule or five capsules of a total lenvatinib amount of 17 mg (namely, three 1 mg capsules, one 4 mg capsule and one 10 mg capsule).
  • the syringe was closed with the cap, and after adding 3 mL of water or the apple juice thereto using another fresh syringe, a piston was pushed into the end of the syringe by about 2 cm, and the syringe was allowed to stand still for about 10 minutes. After standing for 10 minutes, the syringe was shaken for about 3 minutes to dissolve capsule shell. The piston was then pushed into the syringe to remove the air from the syringe, and the thus obtained suspension was taken out of the syringe and then subjected to dilution and centrifugation to prepare a sample liquid.
  • the whole amount of each suspension of the 1 mg, 4 mg or 10 mg capsules was transferred to a 50 mL volumetric flask, and the whole amount of the suspension of the 17 mg capsules (including three 1 mg capsules, one 4 mg capsule and one 10 mg capsule) was transferred to a 200 mL volumetric flask, and the resultant was diluted with a diluent (methanol, water and sodium dihydrogen phosphate dihydrate in 800:200:1 (v/v/w)) to the volume of the flask.
  • the centrifugation was performed after extraction by stirring and an ultrasonic treatment in a water bath.
  • the final lenvatinib concentration of the suspensions of the 1 mg and 4 mg capsules were respectively 0.02 mg/mL and 0.08 mg/mL.
  • the suspension of the 10 mg capsule after performing the centrifugation in the same manner as the suspensions of the 1 mg and 4 mg capsules, 5 mL of a supernatant was transferred to a 10 mL flask and then diluted with the diluent. The final lenvatinib concentration of the suspension of the 10 mg capsule was 0.10 mg/mL.
  • the suspension of 17 mg capsules after performing the centrifugation in the same manner as the suspension of the 10 mg capsule, 5 mL of a supernatant was transferred to a 20 mL flask and then diluted with the diluent.
  • the final lenvatinib concentration of the suspension of the 17 mg capsules was 0.085 mg/mL.
  • the selection of water or the apple juice caused no difference in the recovery. If the rinsing step was not performed, the recovery was lowered. There was no difference whether the rinsing step was performed once or twice, and the recovery of 90% or more was attained if the rinsing step was performed at least once.
  • each of 1 mg, 4 mg and 10 mg capsules was suspended in 3 mL of water or the apple juice in a vial.
  • the whole amount of the resultant suspension at the initial stage or 24 hours after was transferred to a 50 mL volumetric flask, and a diluent (methanol, water and sodium dihydrogen phosphate dihydrate in 800:200:1 (v/v/w)) was added thereto for dilution to the volume of the flask.
  • a diluent methanol, water and sodium dihydrogen phosphate dihydrate in 800:200:1 (v/v/w)
  • the amount of the impurity X was not increased from the initial value even after 24 hours, and hence it was found that the lenvatinib suspension in water or the apple juice was stable for 24 hours.
  • each of 1, 4 and 10 mg lenvatinib capsules or each combination of capsules shown in Table 30 was suspended in a syringe by using 3 mL of water.
  • Results of viscosities (unit: ⁇ /mPas) of the respective suspensions obtained by measurement performed under conditions shown in Table 29 are shown in Table 30.
  • each of 1, 4 and 10 mg lenvatinib capsules or each combination of capsules shown in Table 30 was suspended in a syringe by using 3 mL of water, and then an NG tube was connected to the syringe.
  • Results of an NG tube passability test thus performed are shown in Table 31.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
US15/550,124 2015-02-25 2016-02-23 Method for Suppressing Bitterness of Quinoline Derivative Abandoned US20180028662A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/550,124 US20180028662A1 (en) 2015-02-25 2016-02-23 Method for Suppressing Bitterness of Quinoline Derivative

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562120561P 2015-02-25 2015-02-25
US15/550,124 US20180028662A1 (en) 2015-02-25 2016-02-23 Method for Suppressing Bitterness of Quinoline Derivative
PCT/JP2016/055268 WO2016136745A1 (fr) 2015-02-25 2016-02-23 Procédé de suppression de l'amertume d'un dérivé de quinoléine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/055268 A-371-Of-International WO2016136745A1 (fr) 2015-02-25 2016-02-23 Procédé de suppression de l'amertume d'un dérivé de quinoléine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/038,710 Division US11090386B2 (en) 2015-02-25 2018-07-18 Method for suppressing bitterness of quinoline derivative

Publications (1)

Publication Number Publication Date
US20180028662A1 true US20180028662A1 (en) 2018-02-01

Family

ID=56789022

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/550,124 Abandoned US20180028662A1 (en) 2015-02-25 2016-02-23 Method for Suppressing Bitterness of Quinoline Derivative
US16/038,710 Active US11090386B2 (en) 2015-02-25 2018-07-18 Method for suppressing bitterness of quinoline derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/038,710 Active US11090386B2 (en) 2015-02-25 2018-07-18 Method for suppressing bitterness of quinoline derivative

Country Status (24)

Country Link
US (2) US20180028662A1 (fr)
EP (1) EP3263106B1 (fr)
JP (1) JP6792546B2 (fr)
KR (2) KR102763349B1 (fr)
CN (1) CN107427505A (fr)
AU (1) AU2016224583B2 (fr)
BR (1) BR112017017428A2 (fr)
CA (1) CA2976325C (fr)
DK (1) DK3263106T3 (fr)
ES (1) ES2967362T3 (fr)
FI (1) FI3263106T3 (fr)
HR (1) HRP20231692T1 (fr)
HU (1) HUE064614T2 (fr)
IL (2) IL253946B1 (fr)
LT (1) LT3263106T (fr)
MX (1) MX385403B (fr)
PL (1) PL3263106T3 (fr)
PT (1) PT3263106T (fr)
RS (1) RS65049B1 (fr)
RU (1) RU2017128583A (fr)
SG (1) SG11201706630UA (fr)
SI (1) SI3263106T1 (fr)
SM (1) SMT202400005T1 (fr)
WO (1) WO2016136745A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158012A1 (en) * 2020-05-23 2023-05-25 Shilpa Medicare Ltd Oral liquid formulations of lenvatinib

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200345637A1 (en) * 2018-01-19 2020-11-05 Aiviva Biopharma, Inc. Suspension compositions of multi-target inhibitors
CN112190583B (zh) * 2019-07-08 2021-10-29 成都苑东生物制药股份有限公司 一种乐伐替尼药物组合物及其制备方法

Family Cites Families (358)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB1458148A (en) 1974-04-19 1976-12-08 Wyeth John & Brother Ltd Carbocyclic-fused ring quinoline derivatives
JPS57123267A (en) 1981-01-23 1982-07-31 Kansai Paint Co Ltd Thermosetting paint composition
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3587022T2 (de) 1984-02-17 1993-06-17 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
DE8411409U1 (de) 1984-04-11 1984-08-30 Dr.-Ing. Walter Frohn-Betriebe, 8000 München Entgasungsventil fuer lager- und/oder transportbehaelter
US4563417A (en) 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
ATE37196T1 (de) 1984-11-22 1988-09-15 Holsten Brauerei Ag Bier und verfahren zu dessen herstellung.
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
JPS61148115A (ja) 1984-12-21 1986-07-05 Tooa Eiyoo Kk 難溶性薬物の徐放性製剤及びその製造法
JPS62168137A (ja) 1985-12-20 1987-07-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料およびその処理方法
CH656535A5 (en) 1986-01-24 1986-07-15 Spirig Ag Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water
JPH07106295B2 (ja) 1986-07-22 1995-11-15 エーザイ株式会社 調湿剤
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
CA1339136C (fr) 1987-07-01 1997-07-29 Sailesh Amilal Varia Forme amorphe de l'aztreonam
US5009894A (en) 1988-03-07 1991-04-23 Baker Cummins Pharmaceuticals, Inc. Arrangement for and method of administering a pharmaceutical preparation
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US4983615A (en) 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
EP0408496A3 (en) 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
AU1248292A (en) 1990-12-06 1992-07-08 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
GB9105677D0 (en) 1991-03-19 1991-05-01 Ici Plc Heterocyclic compounds
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
JPH04341454A (ja) 1991-05-16 1992-11-27 Canon Inc シート収納装置
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5211951A (en) 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
JPH05194259A (ja) * 1991-08-30 1993-08-03 Mitsubishi Kasei Corp 抗消化性潰瘍剤
US5200194A (en) 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
AU678764B2 (en) 1992-06-03 1997-06-12 Case Western Reserve University Bandage for continuous application of biologicals
TW271400B (fr) 1992-07-30 1996-03-01 Pfizer
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06153952A (ja) 1992-11-26 1994-06-03 Nobuaki Tamamaki 微量未知二重鎖ｄｎａ分子の増幅、標識を行うための前処理方法
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
ATE178794T1 (de) 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
JPH07176103A (ja) 1993-12-20 1995-07-14 Canon Inc 光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
JP3660391B2 (ja) 1994-05-27 2005-06-15 株式会社東芝 半導体装置の製造方法
JPH0848078A (ja) 1994-08-05 1996-02-20 Nippon Paper Ind Co Ltd 感熱記録体
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5656454A (en) 1994-10-04 1997-08-12 President And Fellows Of Harvard College Endothelial cell-specific enhancer
JP3207058B2 (ja) 1994-11-07 2001-09-10 財団法人国際超電導産業技術研究センター 超電導体薄膜及びその製造方法
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
JPH08176138A (ja) 1994-12-19 1996-07-09 Mercian Corp イソクマリン誘導体
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US5658374A (en) 1995-02-28 1997-08-19 Buckman Laboratories International, Inc. Aqueous lecithin-based release aids and methods of using the same
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US6579314B1 (en) 1995-03-10 2003-06-17 C.R. Bard, Inc. Covered stent with encapsulated ends
EP3103799B1 (fr) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Derives de quinazoline
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JPH0923885A (ja) 1995-07-12 1997-01-28 Dai Ichi Seiyaku Co Ltd 遺伝子発現ライブラリー及びその製造法
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
AU7340096A (en) 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JPH09234074A (ja) 1996-03-04 1997-09-09 Sumitomo Electric Ind Ltd アダプター二本鎖ｄｎａ及びそれを用いたｄｎａ増幅方法
ES2218677T3 (es) 1996-04-17 2004-11-16 Bristol-Myers Squibb Pharma Company Derivados de n-(amidinofenil)-n'-(subst.)-3h-2,4-benzodiazepin-3-ona como inhibidores del factor xa.
AU3568897A (en) 1996-06-07 1998-01-05 Eos Biotechnology, Inc. Immobilised linear oligonucleotide arrays
EP0912175A4 (fr) 1996-06-28 1999-09-08 Merck & Co Inc Antagonistes du recepteur de fibrinogene
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ATE227283T1 (de) 1996-07-13 2002-11-15 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
JPH10147524A (ja) 1996-09-20 1998-06-02 Nippon Kayaku Co Ltd フォルスコリン誘導体含有経口製剤及び医薬製剤の製法
CA2263479A1 (fr) 1996-09-25 1998-04-02 Zeneca Limited Derives quinolines inhibant les effets de facteurs de croissance tels que le facteur de croissance endotheliale vasculaire
AU725138B2 (en) 1996-09-30 2000-10-05 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
JPH10114655A (ja) 1996-10-09 1998-05-06 Kyowa Hakko Kogyo Co Ltd 固形製剤
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
BR9713552A (pt) 1996-11-27 2000-01-25 Pfizer Derivados de pirimidina bicìclicos condensados
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
AU6248798A (en) 1997-01-29 1998-08-18 Eli Lilly And Company Treatment for premenstrual dysphoric disorder
JP3040486U (ja) 1997-02-13 1997-08-19 有限会社ザップ フィッシングジャケット
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP0968206B8 (fr) 1997-02-19 2007-01-24 Berlex, Inc. Derives n-heterocycliques utiles en tant qu'inhibiteurs de la no synthetase
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
AU7526798A (en) 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
JPH10316576A (ja) 1997-05-13 1998-12-02 Nissui Pharm Co Ltd キトサン含有錠剤
DE69826695T2 (de) 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
TR199903025T2 (xx) 1997-06-10 2000-07-21 Synthon B.V. 4-Fenilpiperidin bile�imleri.
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
WO1999001738A2 (fr) 1997-06-30 1999-01-14 University Of Maryland, Baltimore Facteur de croissance epidermique fixant l'heparine dans le diagnostic de la cystite interstitielle
BE1011251A3 (fr) 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP3765918B2 (ja) 1997-11-10 2006-04-12 パイオニア株式会社 発光ディスプレイ及びその駆動方法
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
ES2154253T3 (es) 1997-12-22 2012-01-27 Bayer Healthcare Llc Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
IL136768A0 (en) 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
IL136690A0 (en) 1997-12-22 2001-06-14 Bayer Ag Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
CN100360507C (zh) 1997-12-22 2008-01-09 拜尔有限公司 用取代杂环脲抑制raf激酶
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
TR200002447T2 (tr) 1998-02-25 2000-11-21 Genetics Institute, Inc. Fosfolinaz enzimlerinin inhibitörleri
AU741992B2 (en) 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
JPH11322596A (ja) 1998-05-12 1999-11-24 Shionogi & Co Ltd 白金錯体および環状リン酸エステルアミドを含有する抗癌剤
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
BRPI9911326B8 (pt) 1998-06-17 2021-05-25 Eisai Co Ltd análogos macrocíclicos e métodos para seu uso e preparação
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
TR200100931T2 (tr) 1998-10-01 2001-10-22 Novartis Ag Yeni sürekli salınımlı oral formülasyonlar
US6344455B1 (en) 1998-11-19 2002-02-05 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, and irreversible inhibitor of tyrosine kinases
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
ATE253051T1 (de) 1999-01-22 2003-11-15 Kirin Brewery Chinolinderivate und chinazolinderivate
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
CZ305827B6 (cs) 1999-02-10 2016-03-30 Astrazeneca Ab Indolové deriváty
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
JP2000328080A (ja) 1999-03-12 2000-11-28 Shin Etsu Chem Co Ltd シートベルト用低摩擦化処理剤
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
ATE269357T1 (de) 1999-04-28 2004-07-15 Univ Texas Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
AU4778500A (en) 1999-05-20 2000-12-12 Takeda Chemical Industries Ltd. Composition containing ascorbic acid salt
JP4304357B2 (ja) 1999-05-24 2009-07-29 独立行政法人理化学研究所 完全長ｃＤＮＡライブラリーの作成法
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001047890A (ja) 1999-08-06 2001-02-20 Toyota Motor Corp 車両用パワープラントの制御装置
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AR025752A1 (es) 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
JP2001131071A (ja) 1999-10-29 2001-05-15 Meiji Seika Kaisha Ltd 非晶質および非晶質を含有する医薬組成物
US20080241835A1 (en) 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
JP2003525595A (ja) 1999-11-01 2003-09-02 キュラゲン コーポレイション 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法
ES2292488T3 (es) 1999-11-16 2008-03-16 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de la urea, como agentes antiinflamatorios.
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
AU784266B2 (en) 1999-12-22 2006-03-02 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine kinase
TWI281915B (en) 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
AU2223501A (en) 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
BRPI0108394B8 (pt) 2000-02-15 2021-05-25 Upjohn Co inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
JP3657203B2 (ja) 2000-04-21 2005-06-08 エーザイ株式会社 銅クロロフィリン塩含有液剤組成物
CN1116047C (zh) 2000-06-05 2003-07-30 华中科技大学 用泥鳅制成的护肝功能食品及其制备方法
US20020040127A1 (en) 2000-06-09 2002-04-04 Yuqiu Jiang Compositions and methods for the therapy and diagnosis of colon cancer
WO2002016348A1 (fr) 2000-08-09 2002-02-28 Astrazeneca Ab Derives bicycliques antiangiogeniques
WO2002032872A1 (fr) 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
PT1339458E (pt) 2000-11-22 2007-11-09 Novartis Ag Combinação compreendendo um agente para diminuir a actividade do vegf e um agente para diminuir a actividade do egf
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
US6544552B2 (en) 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
JP4808365B2 (ja) 2001-03-02 2011-11-02 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｐｃｒ法
EP1490362A2 (fr) 2001-03-08 2004-12-29 Millennium Pharmaceuticals, Inc. Composes de quinoline heterocycliques contenant de l'azote
PT1385551E (pt) 2001-04-06 2008-11-03 Wyeth Corp Associações antineoplásicas compreendendo cci-779 (derivado de rapamicina) associado a gemcitabina ou fluorouracilo
WO2002085926A2 (fr) 2001-04-19 2002-10-31 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Procede de production de series d'anticorps stables regenerables
PL209822B1 (pl) 2001-04-27 2011-10-31 Kirin Pharma Kk Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie
JP3602513B2 (ja) 2001-04-27 2004-12-15 麒麟麦酒株式会社 アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
JP2003026576A (ja) 2001-05-09 2003-01-29 Eisai Co Ltd 味覚改善製剤
US6812341B1 (en) 2001-05-11 2004-11-02 Ambion, Inc. High efficiency mRNA isolation methods and compositions
AU2002342335B2 (en) 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AU2002313249B2 (en) 2001-06-22 2008-08-21 Kirin Pharma Kabushiki Kaisha Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
GB0117144D0 (en) 2001-07-13 2001-09-05 Glaxo Group Ltd Process
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
JP4827154B2 (ja) 2001-07-25 2011-11-30 株式会社オーイズミ 遊技装置
JP3088018U (ja) 2001-08-02 2002-08-30 ユーエス工業株式会社 垂木支持用ブラケットを備えたパイプバンド
GB0119467D0 (en) 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
EP1436620B1 (fr) 2001-09-10 2014-04-23 Meso Scale Technologies, LLC Procedes et appareils permettant de realiser de multiples mesures sur un echantillon
CA2460845A1 (fr) 2001-09-20 2003-03-27 Ab Science Utilisation d'inhibiteurs c-kit puissants, selectifs et non toxiques pour le traitement de la cystopathie interstitielle sous-muqueuse
JP4130179B2 (ja) 2001-09-27 2008-08-06 ノバルティス アクチエンゲゼルシャフト 骨髄腫を処置するためのｃ−ｋｉｔ阻害剤の使用
AU2002341881B2 (en) 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
WO2003030908A2 (fr) 2001-10-09 2003-04-17 The University Of Cincinnati Methode de traitement du cancer thyroidien
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003033472A1 (fr) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
CA2467573A1 (fr) 2001-11-27 2003-06-19 Wyeth Holdings Corporation 3-cyanoquinolines en tant qu'inhibiteurs de kinases egf-r et her2
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
WO2003075840A2 (fr) 2002-03-04 2003-09-18 Imclone Systems Incorporated Anticorps humains specifiques de kdr et leurs utilisations
JP2003252737A (ja) 2002-03-04 2003-09-10 Shin Etsu Chem Co Ltd 口腔用組成物
WO2003074045A1 (fr) 2002-03-05 2003-09-12 Eisai Co., Ltd. Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese
CN100337630C (zh) 2002-03-12 2007-09-19 布里斯托尔-迈尔斯斯奎布公司 可口的口服悬浮液及其制备方法
AU2003226676A1 (en) 2002-03-20 2003-09-29 Dana-Farber Cancer Institute Inc. Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
JPWO2003093238A1 (ja) 2002-05-01 2005-09-08 麒麟麦酒株式会社 マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
WO2004006862A2 (fr) 2002-07-16 2004-01-22 Children's Medical Center Corporation Methode de modulation de l'angiogenese
KR20050037557A (ko) 2002-07-22 2005-04-22 아스펜 에어로겔, 인코퍼레이티드 폴리이미드 에어로겔, 탄소 에어로겔 및 금속 카바이드에어로겔, 및 이들의 제조방법
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7252976B2 (en) 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
BR0313871A (pt) 2002-08-30 2005-07-19 Eisai Co Ltd Derivados aromáticos contendo nitrogênio
KR20050051688A (ko) 2002-10-09 2005-06-01 코산 바이오사이언시즈, 인코포레이티드 에포틸론(Еｐｏ) Ｄ ＋ 5-플루오로우라실(ＦＵ)/겜시타빈
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
JP4749660B2 (ja) 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
DE60305724T2 (de) 2002-10-21 2006-11-09 Warner-Lambert Co. Llc Tetrahydrochinolin-derivate als crth2 antagonisten
US20080207617A1 (en) 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
MXPA05004919A (es) 2002-11-06 2005-08-18 Cyclacel Ltd Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
ITSV20020056A1 (it) 2002-11-14 2004-05-15 Alstom Transp Spa Dispositivo e metodo di verifica di motori software logici di comando di impianti ferroviari, in particolare di impianti di stazione
AR042042A1 (es) 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
ITMI20022447A1 (it) 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
KR20040053908A (ko) 2002-12-16 2004-06-25 엘지전자 주식회사 열교환기의 응축수 배출구조
AU2004206860B2 (en) 2003-01-14 2010-03-18 Cytokinetics, Inc. Compounds, compositions and methods
JP3581361B1 (ja) 2003-02-17 2004-10-27 株式会社脳機能研究所 脳活動測定装置
US20040162333A1 (en) 2003-02-19 2004-08-19 Naima Mezaache Rapid absorption selective 5-HT agonist formulations
DK2476667T3 (da) 2003-02-26 2014-09-15 Sugen Inc Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
NZ542407A (en) 2003-03-05 2008-08-29 Celgene Corp Diphenylethylene compounds and uses thereof
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
CN1761682A (zh) 2003-03-14 2006-04-19 大正制药株式会社 单克隆抗体与产生该单克隆抗体的杂交瘤
NZ542304A (en) 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
CN1744881A (zh) * 2003-04-02 2006-03-08 普利瓦研究与发展有限公司 苦味减轻了的药物组合物
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
WO2004101526A1 (fr) 2003-04-22 2004-11-25 Eisai Co., Ltd. Cristal polymorphe de 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide et procede de preparation
KR100503949B1 (ko) 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
EP1473043A1 (fr) 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Combinaison pharmaceutique pour le traitement de maladies liées à la prolifération cellulaire, la migration ou l'apoptose de cellules de myélomes ou l'angiogenèse
US7107104B2 (en) 2003-05-30 2006-09-12 Medtronic, Inc. Implantable cortical neural lead and method
JP2005008534A (ja) 2003-06-17 2005-01-13 Soc De Conseils De Recherches & D'applications Scientifiques (Scras) 抗癌剤及び癌の治療方法
AU2004255022B2 (en) 2003-07-10 2007-08-23 Astrazeneca Ab Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
JP2007502809A (ja) 2003-08-15 2007-02-15 アブ サイエンス ＩＩ型糖尿病を治療するためのｃ−ｋｉｔ阻害剤の使用方法
US7485658B2 (en) 2003-08-21 2009-02-03 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
KR20060121818A (ko) 2003-08-21 2006-11-29 오에스아이 파마슈티컬스, 인코포레이티드 Ｎ-치환된 벤즈이미다졸릴 ｃ-ｋｉｔ 억제제
DE602004017623D1 (de) 2003-08-21 2008-12-18 Osi Pharm Inc N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitoren
US7312243B1 (en) 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
CA2537991A1 (fr) 2003-09-23 2005-03-31 Novartis Ag Polytherapie combinant un inhibiteur des recepteurs du facteur vegf avec un agent chimiotherapeutique
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
KR200340552Y1 (ko) 2003-10-08 2004-02-11 주식회사 엘지화학 창틀 내부에 블라인드 및 방범창 설치가 용이한 이중창틀
JP2005124034A (ja) 2003-10-20 2005-05-12 Nippon Telegr & Teleph Corp <Ntt> 発信者の特定及び発信者への呼び返しを可能とする回線設定方法
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
AU2004292773A1 (en) 2003-11-28 2005-06-09 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
KR100870681B1 (ko) 2003-12-25 2008-11-26 에자이 알앤드디 매니지먼트 가부시키가이샤 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의결정 및 이들의 제조 방법
UA86614C2 (ru) 2004-01-23 2009-05-12 Амген Инк Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
AU2005217325B2 (en) 2004-02-27 2007-11-29 Eisai R & D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (1)
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
ES2311992T3 (es) 2004-05-21 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.
WO2005117887A1 (fr) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Traitement a base de gemcitabine et d'un inhibiteur de egfr
US20080214606A1 (en) * 2004-06-18 2008-09-04 The Government of the United States of America as represented by The Secretary of the Dept. of ..... Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20050288521A1 (en) 2004-06-29 2005-12-29 Phytogen Life Sciences Inc. Semi-synthetic conversion of paclitaxel to docetaxel
CA2572331A1 (fr) 2004-07-02 2006-02-09 Exelixis, Inc. Modulateurs de c-met et leur methode d'utilisation
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030941A1 (fr) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. Utilisation concomitante d'un compose contenant du sulfonamide et d'un inhibiteur d'angiogenese
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
ATE428421T1 (de) * 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
US20070298111A1 (en) 2004-10-01 2007-12-27 Eisai R&D Management Co., Ltd. Fine Particle-Containing Composition and Manufacturing Method Therefor
JP2008520188A (ja) 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド アンジオポエチン−２特異的結合物質
AU2005336924A1 (en) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists
ATE445397T1 (de) 2004-11-23 2009-10-15 Dong Wha Pharm Co Ltd N-hydroxy-4-ä5-ä4-(5-isopropyl-2-methyl-1,3- thiazol-4-yl)phenoxyüpentoxyübenzamidin 2 methansulfonsauresalz
CA2587642C (fr) 2004-11-30 2013-04-09 Amgen Inc. Heterocycles substitues et methodes d'utilisation
CN100341504C (zh) 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP1824843A2 (fr) 2004-12-07 2007-08-29 Locus Pharmaceuticals, Inc. Inhibiteurs de proteines kinases
DK1838733T3 (da) 2004-12-21 2011-11-28 Medimmune Ltd Antistoffer rettet mod angiopoietin-2 og anvendelser deraf
US20060198885A1 (en) 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
JP2006230816A (ja) 2005-02-25 2006-09-07 H & A Investment:Kk サンダル用ホルダー
JP5106098B2 (ja) 2005-02-28 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の抗癌剤との新規併用
WO2006090930A1 (fr) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Nouvelle utilisation combinee d'un compose de sulfonamide
US20080286282A1 (en) 2005-02-28 2008-11-20 Eisai R & D Management Co., Ltd. Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
PT1883397E (pt) * 2005-05-17 2010-02-23 Actelion Pharmaceuticals Ltd Comprimido dispersível de bosentano
CA2608733A1 (fr) 2005-05-17 2007-02-01 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations
DK2395004T3 (en) 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
WO2006137474A1 (fr) 2005-06-23 2006-12-28 Eisai R & D Management Co., Ltd. Sel amorphe du 4-(3-chloro-4-(cyclopropylaminocarbonyl)­aminophénoxy)-7-méthoxy-6-quinolinecarboxamide et procédé de synthèse dudit sel
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
EP1926494A2 (fr) 2005-06-29 2008-06-04 Carlo Pedone Composes modulant le recepteur de vegf et utilisation de ceux-ci
EP1901719A2 (fr) 2005-07-11 2008-03-26 Nycomed Danmark ApS Formulation de benzimidazole
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007014335A2 (fr) 2005-07-27 2007-02-01 The University Of Texas System Combinaisons comportant de la gemcitabine et des inhibiteurs la tyrosine kinase pour le traitement du cancer du pancreas
JP5066446B2 (ja) 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (fr) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Composition pharmaceutique anti-tumeur avec des inhibiteurs d'angiogénèse
ES2424651T3 (es) 2005-08-24 2013-10-07 Eisai R&D Management Co., Ltd. Nuevo derivado de piridina y derivado de pirimidina (3)
KR100990590B1 (ko) 2005-09-01 2010-10-29 에자이 알앤드디 매니지먼트 가부시키가이샤 붕해성이 개선된 의약 조성물의 제조 방법
CN1308012C (zh) 2005-11-02 2007-04-04 广州中医药大学第二附属医院 一种治疗脑出血的中药组合物及其制备方法
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (fr) 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Agent antitumeur pour myelomes multiples
PL1959955T3 (pl) 2005-12-05 2011-04-29 Pfizer Prod Inc Sposób traktowania nieprawidłowego wzrostu komórek
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
RU2437657C2 (ru) 2006-03-16 2011-12-27 Новартис Аг Твердая лекарственная форма, содержащая активный агент с маскированным вкусом
KR100728926B1 (ko) 2006-03-20 2007-06-15 삼성전자주식회사 3축 힌지 구조를 갖는 휴대용 전자기기
ES2556173T3 (es) 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
EP2062886B1 (fr) 2006-08-23 2011-11-30 Eisai R&D Management Co., Ltd. Sel de derive de phenoxypyridine ou son cristal et procede de production
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
JP2010502209A (ja) 2006-09-07 2010-01-28 アストラゼネカ アクチボラグ Ｒｅｔレセプターチロシンキナーゼを標的とする薬剤による治療のために患者を評価する方法
WO2008045566A1 (fr) * 2006-10-12 2008-04-17 Ptc Therapeutics, Inc. Procédés pour doser le 1,2,4-oxadiaozle actif par voie orale pour la thérapie de suppression des mutations non-sens
JP2009184925A (ja) * 2006-11-02 2009-08-20 Dai Ichi Seiyaku Co Ltd ５−（１ｈ−１，２，３−トリアゾール−４−イル）−１ｈ−ピラゾール誘導体
JPWO2008088088A1 (ja) 2007-01-19 2010-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 膵癌治療用組成物
ES2547303T3 (es) 2007-01-19 2015-10-05 Ardea Biosciences, Inc. Inhibidores de MEK
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
US20120232049A1 (en) 2007-02-23 2012-09-13 Eisai R&D Management Co., Ltd. Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene
EP2133095A4 (fr) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd Composition pharmaceutique
WO2008108386A1 (fr) 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. Composition pharmaceutique
GB2448181B (en) 2007-04-05 2011-11-09 Ford Global Tech Llc Vehicle headlight beam controls
US7807172B2 (en) 2007-06-13 2010-10-05 University Of Washington Methods and compositions for detecting thyroglobulin in a biological sample
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
EP2175885B1 (fr) 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations
EP2218712B1 (fr) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combinaison d'une substance antiangiogénique et d'un complexe de platine antitumoral
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
BRPI0906576A2 (pt) 2008-01-29 2015-07-07 Eisai R&D Man Co Ltd Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
GB2456907A (en) 2008-01-30 2009-08-05 Astrazeneca Ab Method for determining subsequent VEGFR2 inhibitor therapy comprising measuring baseline VEGF level.
EP2259844A4 (fr) 2008-03-05 2012-02-01 Vicus Therapeutics Llc Compositions et procédés pour des thérapies de la mucosite et d oncologie
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201001639A1 (ru) 2008-04-14 2011-06-30 Арди Байосайенсиз, Инк. Композиции и способы их получения и применения
JP2009263298A (ja) 2008-04-28 2009-11-12 Ss Pharmaceut Co Ltd 不快な味を隠ぺいした経口組成物
US8637554B2 (en) 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer
US20110104161A1 (en) 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2009150256A1 (fr) 2008-06-13 2009-12-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Marqueurs permettant de prévoir la réponse et la survie chez des patients subissant un traitement anti-egfr
WO2010006225A1 (fr) 2008-07-11 2010-01-14 Novartis Ag Combinaison de (a) un inhibiteur de phosphoinositide 3-kinase et de (b) un modulateur de voie ras/raf/mek
JP5439494B2 (ja) 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
WO2010086964A1 (fr) 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 Thérapie de combinaison pour traitement d'un cancer
US20120164148A1 (en) 2009-08-07 2012-06-28 The Wistar Institute Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer
PL2468281T3 (pl) * 2009-08-19 2016-06-30 Eisai R&D Man Co Ltd Kompozycja farmaceutyczna zawierająca pochodną chinoliny
US20120207753A1 (en) 2009-08-21 2012-08-16 Centre Hospitalier Universitaire Vaudois Methods of using cd44 fusion proteins to treat cancer
EP2293071A1 (fr) 2009-09-07 2011-03-09 Universität Zu Köln Biomarkers pour le cancer colorectal
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CN103003262A (zh) 2010-07-16 2013-03-27 协和发酵麒麟株式会社 含氮芳香族杂环衍生物
CN103140761B (zh) 2010-07-19 2015-11-25 霍夫曼-拉罗奇有限公司 贝伐单抗组合疗法用于治疗胰腺癌的血浆生物标志物
EP2824457A1 (fr) 2010-07-19 2015-01-14 F. Hoffmann-La Roche AG Méthode d'identification d'un patient présentant une probabilité accrue de répondre à un traitement anticancéreux
WO2012010549A1 (fr) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Méthode d'identification d'un patient présentant une probabilité accrue de répondre à un traitement anticancéreux
RU2013106938A (ru) 2010-07-19 2014-08-27 Ф.Хоффманн-Ля Рош Аг Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы
WO2012019300A1 (fr) 2010-08-10 2012-02-16 Siu K W Michael Marqueurs biologiques d'un cancer endométrial et procédés pour les identifier et les utiliser
WO2012029913A1 (fr) 2010-09-01 2012-03-08 興和株式会社 Préparation orale
US20120077837A1 (en) 2010-09-24 2012-03-29 Eisai R&D Management Co., Ltd. Anti-tumor agent
KR20120077842A (ko) 2010-12-31 2012-07-10 서병윤 천장 크레인용 유압식 장착수단의 작동유 냉각 장치
MX352844B (es) 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
US20120244209A1 (en) 2011-03-02 2012-09-27 Roth Jack A Tusc2 therapies
WO2012122444A1 (fr) 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combinaison de thérapies immunomodulatrices locales et systémiques pour l'amélioration du traitement du cancer
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
WO2012154935A1 (fr) 2011-05-12 2012-11-15 Eisai R&D Management Co., Ltd. Biomarqueurs prédictifs d'une réactivité ou d'une absence de réactivité à un traitement au lenvatinib ou à son sel pharmaceutiquement acceptable
JP5952810B2 (ja) 2011-05-17 2016-07-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤の効果を予測する方法
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2012290121B2 (en) 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
IN2014MN01706A (fr) 2012-02-28 2015-05-29 Seoul Pharma Co Ltd
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
EP2849784A1 (fr) 2012-05-16 2015-03-25 Boehringer Ingelheim International GmbH Combinaison d'anticorps anti-cd37 avec ice (ifosmamide, carboplatine, etoposide)
SG10201702421TA (en) 2012-10-02 2017-05-30 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
US20140163095A1 (en) 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
EP3939614A1 (fr) 2013-01-18 2022-01-19 Foundation Medicine, Inc. Méthodes de traitement du cholangiocarcinome
JP5654715B1 (ja) 2013-02-28 2015-01-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン誘導体（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＤＥＲＩＶＡＴＩＶＥ）
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
ES2705698T3 (es) 2013-06-26 2019-03-26 Eisai R&D Man Co Ltd Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib
US9174998B2 (en) 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
SG10201806297VA (en) 2014-02-04 2018-08-30 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
WO2016140717A1 (fr) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
JP6126319B1 (ja) 2015-06-23 2017-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 （６Ｓ，９ａＳ）−Ｎ−ベンジル−６−［（４−ヒドロキシフェニル）メチル］−４，７−ジオキソ−８−（｛６−［３−（ピペラジン−１−イル）アゼチジン−１−イル］ピリジン−２−イル｝メチル）−２−（プロプ−２−エン−１−イル）−オクタヒドロ−１Ｈ−ピラジノ［２，１−ｃ］［１，２，４］トリアジン−１−カルボキサミド化合物の結晶
US20200375975A1 (en) 2016-04-15 2020-12-03 Eisai R&D Management Co., Ltd. Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158012A1 (en) * 2020-05-23 2023-05-25 Shilpa Medicare Ltd Oral liquid formulations of lenvatinib
EP4153140A4 (fr) * 2020-05-23 2024-07-17 Shilpa Medicare Limited Formulations liquides orales de lenvatinib

Also Published As

Publication number Publication date
BR112017017428A2 (pt) 2018-04-03
KR20170122734A (ko) 2017-11-06
SI3263106T1 (sl) 2024-02-29
AU2016224583A1 (en) 2017-08-31
IL318343A (en) 2025-03-01
RU2017128583A (ru) 2019-03-25
CA2976325A1 (fr) 2016-09-01
IL253946B1 (en) 2025-02-01
IL253946A0 (en) 2017-10-31
SG11201706630UA (en) 2017-09-28
US11090386B2 (en) 2021-08-17
HUE064614T2 (hu) 2024-04-28
MX2017010474A (es) 2017-11-28
EP3263106B1 (fr) 2023-10-25
KR20250024102A (ko) 2025-02-18
EP3263106A4 (fr) 2018-08-29
PT3263106T (pt) 2024-01-12
HRP20231692T1 (hr) 2024-03-15
PL3263106T3 (pl) 2024-04-02
WO2016136745A1 (fr) 2016-09-01
RU2017128583A3 (fr) 2019-03-25
DK3263106T3 (da) 2024-01-08
KR102763349B1 (ko) 2025-02-07
LT3263106T (lt) 2024-01-10
MX385403B (es) 2025-03-18
EP3263106A1 (fr) 2018-01-03
US20180318422A1 (en) 2018-11-08
AU2016224583B2 (en) 2021-06-03
JPWO2016136745A1 (ja) 2017-11-30
SMT202400005T1 (it) 2024-03-13
FI3263106T3 (fi) 2024-01-03
RS65049B1 (sr) 2024-02-29
ES2967362T3 (es) 2024-04-29
CA2976325C (fr) 2023-07-04
JP6792546B2 (ja) 2020-11-25
CN107427505A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
US12447128B2 (en) Formulations of enzalutamide
US20250144112A1 (en) Suspension for oral administration comprising amorphous tolvaptan
BRPI0908340A2 (pt) composição farmacêutica para fármacos pouco solúveis
US11279682B2 (en) Vortioxetine pyroglutamate
US11090386B2 (en) Method for suppressing bitterness of quinoline derivative
US20230058942A1 (en) Extended release multiparticulates of ranolazine
WO2020239882A1 (fr) Formulation pharmaceutique pour l&#39;acide carglumique
US11690805B2 (en) Multi-particulate pharmaceutical composition of quetiapine
CN101756982A (zh) 一种改善口感且稳定的青蒿琥酯复方药物组合物
EP2558079B1 (fr) Composition sèche de ciprofloxacine pour suspension buvable
US20050261335A1 (en) Carvedilol formulations
Charan et al. Immediate drug release dosage form: A review

Legal Events

Date Code Title Description
AS Assignment

Owner name: EISAI R&D MANAGEMENT CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAGANE, KENTARO;UEKI, YOSUKE;SANO, SHUSUKE;AND OTHERS;SIGNING DATES FROM 20170816 TO 20170825;REEL/FRAME:043495/0617

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION